Business & Finance
Business and FinanceBusiness and Finance 
Thu, May 6, 2010
Mon, January 11, 2010
TAMPA, Fla.--([ BUSINESS WIRE ])--PanGenex Corporation (Pink Sheets: PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it achieved record sales growth in the fourth quarter of 2009. Growth occurred among its three trademarked and patented nutraceutical and dietary supplement product lines: Calci-Clear™, LIPIDEME™ and Omeganol™, which address widespread applications in the $538 Million Soft Tissue Calcification (STC) market.
"Our recent sales success can be attributed to our growing physician referral base. In addition, we have increased the availability of our product lines to include many of the nation's top-selling health food stores and retail chains, along with e-commerce sites"
"Our strong sales growth reinforces our belief that despite a weakened economy, consumers aren't willing to compromise on their health. With skyrocketing health care costs, consumers are focusing more on preventative medicine to avoid costly medical bills and prescriptions associated with major illness and disease," said John Stanton, PanGenex Chairman of the Board. "Our safe, effective and all-natural supplements offer consumers a range of options for achieving and maintaining individual health and well being. Our scientific formulations address universal concerns like lowering cholesterol and reducing coronary arterial calcium, a precursor to heart attack, stroke and other cardiovascular diseases."
"Our recent sales success can be attributed to our growing physician referral base. In addition, we have increased the availability of our product lines to include many of the nation's top-selling health food stores and retail chains, along with e-commerce sites," concluded Stanton.
Nutraceutical sales are on the rise, with some product segments experiencing 20% to 40% growth in 2009, according to a representative of the United Natural Product Alliance. In 2010, global nutraceutical sales are expected to reach $187 million. PanGenex's products address STC, an abnormal hardening or thickening of tissue in the arteries. STC is linked to over 50% of chronic diseases and presently affects 196 Million Americans.
About PanGenex Corporation
PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: [ www.PanGenex.com ], [ www.Calgenex.com ] and [ www.HeartHealthyWorld.com ].
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.